Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer

Despite progress in immunotherapy, identifying patients that respond has remained a challenge. Through analysis of whole-exome and targeted sequence data from 5,449 tumors, we found a significant correlation between tumor mutation burden (TMB) and tumor purity, suggesting that low tumor purity tumor...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Nat Cancer
Autores principales: Anagnostou, Valsamo, Niknafs, Noushin, Marrone, Kristen, Bruhm, Daniel C., White, James R., Naidoo, Jarushka, Hummelink, Karlijn, Monkhorst, Kim, Lalezari, Ferry, Lanis, Mara, Rosner, Samuel, Reuss, Joshua E., Smith, Kellie N., Adleff, Vilmos, Rodgers, Kristen, Belcaid, Zineb, Rhymee, Lamia, Levy, Benjamin, Feliciano, Josephine, Hann, Christine L., Ettinger, David S., Georgiades, Christos, Verde, Franco, Illei, Peter, Li, Qing Kay, Baras, Alexander S., Gabrielson, Edward, Brock, Malcolm V., Karchin, Rachel, Pardoll, Drew M., Baylin, Stephen B., Brahmer, Julie R., Scharpf, Robert B., Forde, Patrick M., Velculescu, Victor E.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2020
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7514475/
https://ncbi.nlm.nih.gov/pubmed/32984843
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s43018-019-0008-8
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares